Background Both long‐acting beta 2‐agonists (LABA) and inhaled corticosteroids (ICS)
have been recommended in guidelines for the treatment of chronic obstructive pulmonary …

Asthma and chronic obstructive pulmonary disease (COPD) have traditionally been viewed
as distinct clinical entities. Recently, however, much attention has been focused on patients …

Rationale: Single-center randomized controlled trials of the Zephyr endobronchial valve
(EBV) treatment have demonstrated benefit in severe heterogeneous emphysema. This is …

Background Bronchodilator responsiveness is a potential phenotypic characteristic of
chronic obstructive pulmonary disease (COPD). We studied whether change in lung function …

Abstract The Global Initiative for Asthma (GINA) is a network of individuals, organizations,
and public health officials that was established to disseminate information about the care of …

Objectives Pulmonary function impairment and chronic respiratory symptoms after
tuberculosis are relatively common in low-income and middle-income countries. We aimed …

Treating people with cardiovascular disease and COPD causes significant clinician anxiety.
β-Blockers save lives in people with heart disease, specifically postinfarction and heart …

Asthma and chronic obstructive pulmonary disease (COPD) are both highly prevalent
diseases worldwide. This issue of Clinics in Chest Medicine discusses different aspects of …

This real-world study evaluated the efficacy of once-daily long-acting β2-agonist
(LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for …

Rationale Criteria for a clinically significant bronchodilator response (BDR) are mainly
based on studies in patients with obstructive lung diseases. Little is known about the BDR in …